Gujarat Kidney and Super Speciality Limited has clarified a typographical error concerning the signing date of its Standalone Financial Statements for Q1FY26. The company confirmed that the actual date of signing by authorised signatories was 28-May-2025, correcting the discrepancy observed by the exchange. The entity stated that this clerical error has no bearing on the financial figures, disclosures, or the substance of the results submitted on 28-May-2026.

The company undertook to publish the corrected Standalone Financial Statements with the accurate signing date on its website. It further assured the exchange that appropriate internal checks would be implemented to prevent the recurrence of such errors in future submissions. The clarification was submitted in response to a communication from the National Stock Exchange of India Limited dated 25/06/2026.

Financial Performance Overview

The financial results for the period ended 31 March 2026 were reviewed by the Audit Committee and approved by the Board. The statutory auditor, M/s Y M Shah & Co., issued an unmodified limited review report. The company reported a total income of ₹969.38 lacs for the quarter ended 31 March 2026, compared to ₹805.73 lacs in the corresponding period of the previous year.

For the full year ended 31 March 2026, the company recorded a total income of ₹4,059.47 lacs, an increase from ₹3,528.11 lacs in the previous year. Profit after tax for the year stood at ₹990.14 lacs, up from ₹910.90 lacs in FY25. The earnings per equity share (basic and diluted) for the year were reported at ₹1.59, compared to ₹1.79 in the prior year.

Key Financial Metrics

Balance Sheet Highlights

The balance sheet as at 31 March 2026 reflects a total asset base of ₹26,607.67 lacs, a significant rise from ₹4,907.22 lacs in the previous year. This increase was primarily driven by a surge in investments, which grew to ₹10,857.85 lacs from ₹151.45 lacs. Total equity also increased substantially to ₹24,645.86 lacs, bolstered by an issue of equity shares amounting to ₹25,079.56 lacs during the year as per the cash flow statement.

Current assets improved to ₹7,163.97 lacs, supported by bank balances of ₹4,172.07 lacs and cash and cash equivalents of ₹741.56 lacs. On the liabilities side, current borrowings stood at ₹1,296.20 lacs, while lease liabilities were recorded at ₹311.60 lacs in total.

Gujarat Kidney and Super Speciality Limited has secured shareholder approval to alter the objects and terms of utilisation for its Initial Public Offering (IPO) proceeds. The special resolution was passed via a postal ballot conducted through remote e-voting, which concluded on July 04, 2026. This decision authorises the company to modify the deployment of funds raised during its public issue.

The resolution received overwhelming support, with 99.9995% of the total valid votes cast in favour. A total of 56,894,699 votes were polled in favour, while 286 votes were cast against the proposal. The voting process was managed by MUFG Intime India Private Limited, and the scrutinizer's report confirmed the results.

Voting Breakdown

The participation was spread across different shareholder categories, with the promoter group casting all their votes in favour of the resolution. Public non-institutions showed significant support, with 99.9441% of the votes polled from this category favouring the change.

Procedural Details

The remote e-voting process commenced on June 05, 2026, and concluded on July 04, 2026. The cut-off date for determining shareholder eligibility was May 29, 2026. Ashish Doshi, Partner of SPANJ & Associates, Company Secretaries, served as the scrutinizer for the postal ballot process. The company disclosed that no votes were declared invalid or abstained from the voting process.